Related Experiment Video
Updated: Sep 28, 2025
07:59
Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads
Published on: July 21, 2017
9.8K
Exercise to Lower Postprandial Lipemia: Why, When, What and How.
Anatoli Petridou1, Vassilis Mougios1
1School of Physical Education and Sport Science at Thessaloniki, Laboratory of Evaluation of Human Biological Performance, Aristotle University of Thessaloniki, Thessaloniki, Greece.
International Journal of Sports Medicine
|March 28, 2022
Summary
Regular exercise significantly lowers postprandial lipemia (PPL), a risk factor for heart disease. Performing exercise the day before a meal is most effective for reducing PPL levels.
Area of Science:
- Exercise Physiology
- Metabolic Health
- Cardiovascular Disease Prevention
Background:
- Postprandial lipemia (PPL) is an independent risk factor for cardiovascular disease.
- Understanding the impact of exercise on PPL is crucial for metabolic health management.
Approach:
- This review synthesizes recent findings on exercise's efficacy in lowering PPL.
- It addresses the timing, type, and mechanisms of exercise interventions for PPL reduction.
Key Points:
- Exercise is most effective when performed the day before a high- or moderate-fat meal, with benefits lasting up to two days.
- While various exercise types (continuous, intermittent, resistance, short bouts) lower PPL, submaximal, high-volume interval exercise may be superior.
- Exercise reduces PPL by decreasing the circulation of triacylglycerol-rich lipoproteins.
Conclusions:
- Frequent exercise is recommended to maintain the PPL-lowering benefits.
- Exercise plays a vital role in managing PPL and mitigating cardiovascular risk.
More Related Videos
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
297
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
297
01:23Dipeptidyl Peptidase 4 Inhibitors
274
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
274
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
925
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
925
01:18Metabolic States of the Body: The Postabsorptive State
635
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
635
01:24Glucagon-like Receptor Agonists
451
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
451
01:26Atherosclerosis III: Management
54
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
54